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Introduction: The duration of bronchodilator action of the long-acting b-agonist
formoterol when administered in the evening has not been investigated. In this study
we have investigated whether a single evening dose of formoterol, administered
from the combination budesonide/formoterol (BUD/F) Turbuhaler significantly
attenuates the circadian rhythm in airway tone over 24 h.
Methods: Twenty subjects with mild to moderate asthma (mean FEV1 84%
predicted) participated in a double-blind, placebo-controlled, cross-over study.
Subjects inhaled, in random order, placebo or BUD/F (2 100/6 mg) administered in
the evening (2000 h) on two separate occasions. Lung function measurements
including FEV1, specific airways conductance (sGaw) and maximum expiratory flow
at 25–75% of vital capacity (MEF25–75%) were assessed at baseline, at 1 h and
subsequently every 4 h post-dose for 24 h.
Results: Compared with placebo, BUD/F significantly improved the three measures
of airways function throughout the 24 h period, with a difference in FEV1 at 24 h of
0.20 L (0.04–0.35 L). BUD/F attenuated the biphasic pattern of the circadian rhythm
in airway tone.
Conclusion: The single evening administration of formoterol from the combination
BUD/F inhaler resulted in a duration of bronchodilation of at least 24 h.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Recent international and national consensus
guidelines have recognised the relatively flat
dose–response of inhaled corticosteroids and nowed.
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The 24 h bronchodilation 21recommend the earlier introduction of a long-
acting b-agonist in patients not well controlled on
low to medium doses of inhaled corticosteroids.1,2
This therapy may be administered either as
separate or combination inhalers, the latter repre-
senting a simple and convenient treatment which
ensures that long-acting b-agonist drugs are not
prescribed as monotherapy. Combination therapy
also has the potential to improve compliance as
adherence with prescribed chronic therapy is likely
to improve the fewer medications that are used.3,4
Compliance is a major problem with inhaled
respiratory medication, being in the range of
40–50%5,6 with values as low as 15% having been
reported.7 Compliance with inhaled corticosteroids
is strongly influenced by the number of daily doses 8,9
with reported rates of 71%, 34% and 18% with two,
three and four times daily dosing, respectively.10
Therefore a further step in simplifying asthma
management and improving adherence with pre-
scribed therapy is to reduce the dose frequency to
the minimum necessary to maintain asthma control.
A recent meta-analysis has confirmed that a once
daily administration of budesonide is as effective as
a twice daily regimen, in patients with mild to
moderate asthma.11 This raises the possibility of
the once daily use of a combination budesonide/
formoterol (BUD/F) inhaler, at least in terms of the
inhaled corticosteroid component. However, this
would also depend on whether adequate broncho-
dilation was obtained with the once daily use of the
long-acting b-agonist formoterol.
In this study we have investigated whether the
combination inhaler BUD/F would attenuate the
circadian variation in airway tone and achieve
bronchodilation over 24 h when administered in the
evening.Methods
Subjects
Patients volunteering for this study were recruited
from newspaper advertising and from a database of
asthma volunteers. All subjects had to fulfil the
American Thoracic Society (ATS) diagnostic criteria
for asthma12 and meet the following criteria: age
16–65 years; stable asthma; baseline forced ex-
piratory volume in 1 s (FEV1) X50% predicted;
X15% reversibility in FEV1 (measured 15–30min
after 400 mg of inhaled salbutamol via MDI and
spacer) or a documented history of 15% reversibility
after inhaled b-agonist within 3 months prior to the
start of the study.Exclusion criteria comprised a respiratory tract
infection or asthma exacerbation within 1 month of
entry into the study. Following enrolment, subjects
were withdrawn if their baseline FEV1 on one of the
study days was o50% predicted. The study was
approved by the Wellington Ethics Committee and
written informed consent was obtained from all the
subjects.Study design
This was a double-blind, placebo-controlled, cross-
over study. Subjects were admitted to Bowen
Hospital for 24 h on two occasions and slept
overnight, being woken up for lung function
measurements. There was at least a 3 day interval
between study days. Any patients already taking a
long-acting b-agonist abstained from using this
medication for 2 weeks prior to, and for the
duration of the study. Smoking and drinks contain-
ing caffeine were forbidden on study days. On each
of the study days patients took their normal
morning dose of inhaled corticosteroid but withheld
their evening dose and refrained from using a short-
acting b-agonist within 6 h of baseline measure-
ments.
After the assessment of lung function (1915–
2000 h), patients were instructed to inhale place-
bo, or BUD/F (2 100/6 mg), in random order from
blinded turbuhalers. Patients were dosed at 2000,
2010, 2020, 2030 or 2040 h depending on the
number of subjects studied each night. Patients
were dosed at the same time on each study day
(710min).
Measurements of lung function included FEV1,
specific conductance (sGaw) and maximum expira-
tory flow at 25–75% of vital capacity (MEF2575%).
Lung function was measured at baseline, 1 h post-
dose, and then subsequently every 4 h post-dose
until the next evening (2100, 2400, 0400, 0800,
1200, 1600 and 2000 h). FEV1 was recorded at the
mouth using a pneumotacograph with electronic
integration (Jaeger, Wurzburg, Germany). The
highest value of three technically acceptable
manoeuvres was retained as per ATS guidelines.
sGaw was calculated from airways resistance and
thoracic gas volume, measured with a constant
volume body plethysmograph (Jaeger, Wurzburg,
Germany).Data analysis
The primary outcome variable was FEV1, with sGaw
and MEF2575% representing the secondary outcome
variables. Two forms of mixed linear models were
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Figure 2 Plot of raw mean MEF values for each
treatment arm: placebo (J), BUD/F (K) and fitted
polynomial functions, placebo (—), BUD/F (- - -).
M. Masoli et al.22used to model the cross-over with repeated
measures design. Firstly an analysis of co-variance
model using the baseline reading of the particular
outcome as a covariate, and accounting for the
repeated measures by specifying a variance–covar-
iance matrix. A covariance structure that resulted
in a smaller value of ‘Akaikes information criterion’
was used for each outcome variable. Contrasts
were estimated for the difference between active
treatment and placebo at each of 4, 8, 12, 16, 20
and 24 h. Secondly a random coefficients model was
formed. The best fitting model specified cubic
polynomial functions for the placebo arm, to model
the biphasic pattern of airflow, and a linear
function for the BUD/F arm.13,14 Plots of the fitted
curve together with the mean values at each time
point are shown (Figs. 1–3). SAS version 8.2 was
used.1.2
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Twenty mild to moderate asthmatics with a mean
age of 36 years (18–61) and a mean FEV1 of 84%
(54–115%) were investigated (Table 1). The mean
pre-trial inhaled corticosteroid dose was 585 mg/
day (range 0–2000 mg/day) of BDP or equivalent.
One subject required rescue medication at 0400
(8 h post-dose) on the (second) placebo day and was
withdrawn from the study at that time point.
The baseline values for FEV1, sGaw and MEF2575%
were not significantly different on the two study
days (P40:05). The baseline mean (SD) for FEV1 was
2.91 (0.97) L before inhalation of placebo and 2.88
(0.96) L before inhalation of BUD/F.3.3
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Figure 1 Plot of raw mean FEV1 values for each
treatment arm: placebo (J), BUD/F (K) and fitted
polynomial functions, placebo (—), BUD/F (- - -).
Figure 3 Plot of raw means sGaw values for each
treatment arm: placebo (J), BUD/F (K) and fitted
polynomial functions, placebo (—), BUD/F (- - -).Following the administration of placebo there
was a typical biphasic change in airway tone over
24 h with a nadir around 0400 h (8 h post) and a
peak at around 1200 h (16 h post) (Figs. 1–3). Most
patients in the study demonstrated a significant
circadian variation in their airway calibre despite
routine inhaled corticosteroid therapy with a mean
9% (0.26 L) reduction in FEV1 overnight.
The administration of BUD/F resulted in signifi-
cant bronchodilation throughout the 24 h period
when compared with placebo (Figs. 1–3). Signifi-
cant bronchodilation was observed with all three
measures of lung function (Table 2), with a
difference in FEV1 at 24 h of 0.20 L (0.04–0.35 L)
(Table 3).
ARTICLE IN PRESS
Table 1 Patient characteristics.
Subject no. Sex Age (years) Baseline ICS mg/day
(BDP or equiv)
FEV1 (% pred)
1 F 47 2000 90
2 M 20 1000 115
3 F 56 500 78
4 F 18 500 103
5 M 50 800 98
6 F 46 1000 65
7 M 18 800 90
8 M 20 500 95
9 F 60 400 86
10 M 23 200 89
11 F 26 500 85
12 M 24 1000 79
13 F 21 0 79
14 F 22 1000 73
15 M 36 100 75
16 M 20 500 90
17 F 52 400 103
18 F 47 200 66
19 F 47 1000 54
20 M 61 1000 74
Mean — 36 585 84
Range — 18–61 0–2000 115
Table 2 Airway tone over 24 h.
Time (h) Placebo BUD/F
FEV1 (L) sGaw (1/k Pa.s) FEV1 (L) sGaw (1/k Pa.s)
Baseline 2.91 (0.97) 0.74 (0.25) 2.88 (0.96) 0.76 (0.27)
1 2.85 (0.97) 0.70 (0.22) 3.23 (1.04) 1.14 (0.34)
4 2.77 (0.93) 0.56 (0.23 3.29 (1.01) 1.16 (0.29)
8 2.65 (0.91) 0.51 (0.18) 3.22 (1.00) 1.06 (0.34)
12 2.73 (0.95) 0.52 (0.17) 3.15 (0.97) 0.94 (0.34)
16 2.85 (1.02) 0.65 (0.21) 3.16 (1.01) 0.94 (0.33)
20 2.87 (1.02) 0.66 (0.19) 3.18 (1.02) 0.99 (0.28)
24 2.88 (1.04) 0.68 (0.23) 3.07 (1.04) 0.88 (0.30)
FEV1 ¼ forced expiratory volume in 1 s; sGaw ¼ specific airways conductance.
Mean (standard deviation).
The 24 h bronchodilation 23Discussion
This is the first study to demonstrate a 24 h duration
of bronchodilation with the BUD/F combination
(2 100/6 mg via Turbuhaler) when administered in
the evening. The typical enhanced circadian varia-
tion in airway calibre observed with placebo
was attenuated with the BUD/F combination.
The improvement in FEV1 after 24 h of 0.20 L
suggests that BUD/F may have clinically significant
bronchodilator efficacy throughout the 24 h periodfollowing administration in the evening, at least in
stable asthma.
A number of methodological issues were con-
sidered in the design of this study relevant to the
interpretation of the findings. Placebo was used
due to the marked circadian variation in airway
calibre that occurs in asthma as a result of cyclical
variations in the inflammatory processes within the
airway wall combined with the circadian variation
of vagal activity and endogenous cortisol produc-
tion.15–18 This was apparent in our study in which
ARTICLE IN PRESS
Table 3 Contrasts in effect at 4–24 h for FEV1, sGaw and MEF.
Contrast:
formoterol &
budesonide
minus placebo
(h)
Estimated
difference (95%
CI) FEV1 (L)
P value Estimated
difference (95%
CI) sGaw (1/
k Pa.s)
P value Estimated
difference
(95% CI) MEF
(L/min)
P value
4 0.55 (0.40–0.70) o0.0001 0.59 (0.44–0.73) o0.0001 50.0 (32.7–67.3)o0.0001
8 0.58 (0.42–0.73) o0.0001 0.55 (0.41–0.70) o0.0001 45.9 (28.5–63.2)o0.0001
12 0.43 (0.27–0.58) o0.0001 0.42 (0.27–0.57) o0.0001 32.8 (15.4–50.2) 0.0003
16 0.32 (0.16–0.47) 0.0001 0.29 (0.14–0.43) 0.0002 19.3 (1.9–36.8) 0.03
20 0.32 (0.16–0.47) 0.0001 0.33 (0.18–0.48) o0.0001 24.5 (7.0–42.0) 0.007
24 0.20 (0.04–0.35) 0.014 0.20 (0.05–0.34) 0.008 17.8 (0.3–35.3) 0.05
M. Masoli et al.24patients experienced a mean 9% fall in FEV1 at 4 am
when compared with the 10 pm baseline measure-
ments. The lack of a placebo arm to determine the
baseline circadian rhythm in lung function has
severely limited the interpretation of other time
course studies of long-acting b-agonist drugs.19,20 In
a similar study investigating the bronchodilator
duration of the salmeterol/fluticasone combination
administered in the evening we incorporated a
salbutamol treatment arm to act as a ‘‘control
bronchodilator’’.21 This would have been prefer-
able in the current study, however it was not
undertaken due to the added complexity and the
lack of resources.
Another issue was the use of different measures
of lung function to reflect different sites of the
bronchodilator effect. Measurement of specific
airways conductance was undertaken as this is a
sensitive measure of large airway function which is
measured in the tidal breathing range.22 MEF2575%
was used to assess small airway function, with the
primary outcome variable FEV1 measured to obtain
an integrated assessment of both small and large
airway function.23 A similar bronchodilator dura-
tion of action was observed following BUD/F with
all three methods used to assess airway calibre,
suggesting that significant bronchodilator efficacy
was present throughout airways of varying size.
The decision to administer formoterol from a
combination rather than a separate inhaler was
made due to the clinical preference for prescribing
long-acting b-agonist therapy in combination with
inhaled corticosteroids. The combination inhaler
ensures that formoterol is not prescribed as
monotherapy and encourages compliance with
inhaled corticosteroids through its co-administra-
tion. It would have been of interest to also have
studied the duration of action of formoterol alone
to determine whether the inhaled corticosteroid
component influenced the acute airways responseto formoterol. This was not the objective of the
study and would have required a considerably
greater number of subjects to be adequately
powered.
The 12 mg dose of formoterol was chosen as
studies have demonstrated that this dose provides a
similar magnitude and duration of bronchodilation
as higher doses with fewer side effects and can be
considered to be the optimal maintenance dose in
stable asthma.24,25 The only other placebo-con-
trolled study that has examined the time course of
bronchodilation with formoterol over a 24 h period
used this 12 mg dose.26 In that study, a significant
bronchodilator effect was evident up to 8 h after
the administration of formoterol in the morning.
This comparison would suggest that formoterol has
a greater bronchodilator duration of action when
administered in the evening compared with the
morning, however this would need to be investi-
gated formally in a clinical trial. Similar findings
have been made with salmeterol, in which a 24 h
bronchodilator duration of action has been demon-
strated with evening administration of the salme-
terol/fluticasone combination inhaler,21 but not
with salmeterol administered in the morning.26
Certainly it would intuitively seem more logical for
long-acting b-agonist therapy to be given in the
evening rather than the morning, to protect against
the nocturnal increase in airway inflammation and
deterioration in lung function typically seen in
asthma.27,28
To date only one clinical study has compared the
efficacy of BUD/F given once or twice daily. In this
12 week study of 523 subjects with moderate
persistent asthma using 400–1000 mg/day of inhaled
corticosteroid, there was no significant difference
between a once daily evening administration of
BUD/F (2 200/6) and BUD/F (1 200/6) twice
daily for all clinical outcome measures including
exacerbations.29 This would suggest that a once
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The 24 h bronchodilation 25daily administration of BUD/F in the evening may
be a safe and effective maintenance therapy in the
treatment of mild to moderate asthma.Conclusion
The results of this study show that the combination
BUD/F (2 100/6 mg) via the Turbuhaler adminis-
tered in the evening provides significant improve-
ment in lung function over a 24 h period.References
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